In article 4 of the principal Order (medicinal products that are notprescription only), the following paragraph is inserted after paragraph(1C):—

“(1D)

Notwithstanding Article 3(1)(a), a medicinal product shall notbe a prescription only medicine by reason that it consists of orcontains the substance Hyoscine Butylbromide where—

(a)

its route of administration is internal otherwise than by inhaler;

(b)

it is sold or supplied in a container or package containing notmore than 240 mg; and

(c)

its container or package is labelled to show a maximum daily doseof 80 mg and a maximum dose of 20 mg.”.